Search Results - "Degenhardt, T."

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail by Elewski, B., Brand, S., Degenhardt, T., Curelop, S., Pollak, R., Schotzinger, R., Tavakkol, A., Alonso‐Llamazares, Javier, Ashton, Scott J., Bhatia, Neal, Billings, Michael, Blauvelt, Andrew, Bystol, Norman, Dodson, Brandt, Gold, Michael H., Grande, Kimberly, Jarratt, Michael, Jones, Terry S., Kasper, Maria A., Kempers, Steven E., McConnehey, Brock, Noss, Michael, Pariser, David, Parish, Lawrence, Rich, Phoebe, Ahmad Samady, Joseph, Schlessinger, Joel, Schumacher, Doug, Stein, Kenneth, Strout, Cynthia, Tschen, Eduardo, Tu, John H., Weisfeld, Max

“…Summary Background Onychomycosis is a fungal disease that affects the fingernails and toenails and is predominantly caused by dermatophytes. VT‐1161 is a novel…”
Get full text

17: Efficacy and safety of oral VT-11611 in a randomized phase 2a study in patients with acute vulvovaginal candidiasis: six-month follow-up by Brand, S, Degenhardt, T, Nyirjesy, P, Augenbraun, M, Schotzinger, R

Get full text

Palbociclib in daily clinical use: Real world experience of the breast center at the University Hospital Munich by Hester, A., Koenig, A., Dobler, F., Degenhardt, T., Heidegger-Steger, H., Kurt, A.-G., Kahlert, S., Mahner, S., Harbeck, N., Wuerstlein, R.

Get full text

15: To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC) by Brand, S, Degenhardt, T, Nyirjesy, P, Sobel, J, Handelsman, C, Person, K, Schotzinger, R, Tavakkol, A

Get full text

Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer by Kolben, Thomas, Augustin, D., Armbrust, R., Kolben, T. M., Degenhardt, T., Burgmann, M., Goess, C., Ditsch, N., Kates, R., Harbeck, N., Wuerstlein, R.

“…The purpose of this study was to evaluate the influence of guideline-based prospective use of uPA/PAI-1 on clinical outcome in an intermediate-risk cohort of…”
Get full text

Surgical management of ipsilateral breast tumor recurrence by Kolben, T, Schwarz, T.M, Goess, C, Blume, C, Degenhardt, T, Engel, J, Wuerstlein, R, Ditsch, N, Harbeck, N, Kahlert, S

“…Abstract Purpose Approximately 10–15% of breast cancer patients treated by breast conserving surgery (BCS) and adjuvant radiotherapy (RT) will develop…”
Get full text

Chemical modification of proteins by methylglyoxal by Degenhardt, T P, Thorpe, S R, Baynes, J W

“…Methylglyoxal is formed in vivo by spontaneous decomposition of triose phosphate intermediates in aerobic glycolysis. It may also be formed during oxidative…”
Get more information

PP 30 Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis) by Wuerstlein, R, Gluz, O, Kreipe, H, Kates, R, Degenhardt, T, Liedtke, C, Shak, S, Nitz, U, Harbeck, N

Get full text

Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins by Frye, E B, Degenhardt, T P, Thorpe, S R, Baynes, J W

“…Dicarbonyl compounds such as glyoxal and methylglyoxal are reactive dicarbonyl intermediates in the nonenzymatic browning and cross-linking of proteins during…”
Get full text

N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins by Ahmed, M U, Brinkmann Frye, E, Degenhardt, T P, Thorpe, S R, Baynes, J W

“…Advanced glycation end-products and glycoxidation products, such as Nepsilon-(carboxymethyl)lysine (CML) and pentosidine, accumulate in long-lived tissue…”
Get full text

P178 Prospective comparison of uPA/PAI-1, Ki-67 based molecular classification, Recurrence Score and clinical–pathological characteristics in hormone-receptor (HR) positive primary breast cancer: Pilot phase of the randomized WSG PlanB trial by Liedtke, C, Gluz, O, Kreipe, H, Degenhardt, T, Kates, R, Baehner, R, Clemens, M, Wuerstlein, R, Nitz, U, Harbeck, N

Get full text

Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug by GARDINER, T. A, ANDERSON, H. R, DEGENHARDT, T, THORPE, S. R, BAYNES, J. W, ARCHER, D. B, STITT, A. W

“…To investigate the effect of treatment with the non-steroidal anti-inflammatory drug Sulindac on the early vascular pathology of diabetic retinopathy in the…”
Get full text

Oteseconazole for RVVC in diabetes: post-hoc analysis of safety and clinical response in phase 3 studies by P, Nyirjesy, JD, Sobel, T, Degenhardt, C, Weclaw, K, Person, S, Mcgaurn, S, Brand

Get full text

Long-Term observations of oteseconazole efficacy against recurrent vulvovaginal candidiasis by JD, Sobel, T, Degenhardt, K, Person, S, Curelop, C, Weclaw, S, Mcgaurn, S, Brand

Get full text

55P Molecular risk factors for distant metastases in premenopausal patients with HR+/HER2- EBC by Ni, H., Kumbrink, J., Mayr, D., Seiler, A., Hagemann, F., Degenhardt, T., Sagebiel, S., Wuerstlein, R., Harbeck, N., Eggersmann, T.K.

Get full text

Gene expression profiles in premenopausal women with HR+ HER2− early breast cancer by Ni, H., Kurt, A., Kumbrink, J., Seiler, A., Mayr, D., Degenhardt, T., Hagemann, F., Würstlein, R., Harbeck, N., Eggersmann, T.

Get full text

Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats by Degenhardt, Thorsten P., Fu, Min-Xin, Voss, Edgar, Reiff, Klaus, Neidlein, Richard, Strein, Klaus, Thorpe, Suzanne R., Baynes, John W., Reiter, Rudolf

“…Aminoguanidine, an inhibitor of advanced glycation reactions in vitro, inhibits the development of diabetic complications in animal models of diabetes,…”
Get full text

1592P Willingness to vaccinate and side effects of COVID-19 vaccination in patients with breast cancer and gynecological malignancies by Forster, M., Würstlein, R., König, A., Beyer, S., Degenhardt, T., Burges, A., Trillsch, F., Mahner, S., Harbeck, N., Chelariu-Raicu, A.

Get full text

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial by Harbeck, N., Fasching, P.A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R.E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Schinköthe, T., Schmidt, M., Kieback, Dirk Günter, van Mackelenbergh, Marion Tina, Hielscher, Carsten, Ugur, Mustafa Celalettin, Uleer, Christoph, Zahn, Mark-Oliver, Meyer, Ralf, Kraudelt, Susanne, Stefek, Andrea, Pink, Daniel, Just, Marianne, Kolberg, Hans-Christian, Fehm, Tanja, Malter, Wolfram, Warm, Mathias, Forstbauer, Helmut, Behringer, Dirk, Wortmann, Anke, Rom, Joachim, Lehnert, Antje, Ackermann, Sven, Guth, Dagmar, Simon, Eike, Dünnebacke, Jan, Hönig, Arnd, Ehscheidt, Peter, Gnauert, Karsten, Kühn, Thorsten, von Abel, Ekkehard, Hartkopf, Andreas, Karck, Ulrich, Negwer, Martina, Wacker, Jürgen, Welslau, Manfred, Sagasser, Jaqueline, Heinrichm, Bernhard, Brucker, Cosima, Stauder, Heribert, Gröll, Isolde, Felberbaum, Ricardo, Popovic, Milos, Baerens, Dirk-Toralf, Söling, Ulrike, Zaiss, Matthias, Rauh, Jaqueline, Fietz, Thomas, Schröder, Jan, Voß, Hermann, Mohm, Johannes, Neef, Ute, Rieger, Lorenz, Distelrath, Andrea, Nusch, Arnd, Schmidt, Burkhard, Lüdtke-Heckenkamp, Kerstin, Berghorn, Michael, Busch, Steffi, Schock, Caroline, Metz, Michael, Lorenz, Andreas, Uhlig, Jens, Otremba, Burkhard

“…The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported…”
Get full text

Hirudisins. Hirudin-derived thrombin inhibitors with disintegrin activity by KNAPP, A, DEGENHARDT, T, DODT, J

“…Recombinant hirudin variants have been designed which inhibit alpha-thrombin by the hirudin mechanism and which in addition exhibit disintegrin activity. These…”
Get full text